Title: INSULIN.
1Insulin oral hypoglycaemic
- M.Prasad Naidu
- MSc Medical Biochemistry, Ph.D,.
2Diabetes mellitus - It is a group of
heterogenous disorder in which carbohydrate
metabolism is ?, while that of proteins lipids
are ?. Types - Type I - insulin dependent
DM Type II non insulin dependent DM Type III
DM occurs by other disorders Type IV
gestational DM
3Insulin - Chemistry , biosynthesis secretion
- Chemistry - Insulin is made up of 86
aminoacids , It contain A chain 21 AA, B chain
30 AA, Connecitng Peptide 35 AA. Biosynthesis
- Preproinsulin proinsulin Insulin
C peptide Secretion - Glucose transport to ß
cell by GLUT 2 glucose transporter, it undergoes
further metabolism, it generated ATP. Which
inhibit the activity of K CHANNELS. The
inhibition of K channel induces ß cell membrane
depolarisation, opening of voltage dependent Ca2
channel stimulates insulin secretion.
4(No Transcript)
5- Pharmacological actions -
- Carbohydrate metabolism
- ?glycogenesis ? glycogenolysis
- Protein metabolism
- ? protein break down ?
- Fat metabolism
- ? lipogenesis ?fatty acid synthesis.
6(No Transcript)
7Newer insulin preparations Insulin
syringes Portable pen injections Insulin
pumps Biodegradable microspheres Inhaled
insulins Therapeutic uses - Type 1 diabetes
NPH Regular Insulin Type 2 diabetes - Regular
Insulin Diabetic ketoacidosis Tr. IV fluids,
Kcl, sodium bicarbonate, phoshate Non
ketonic hyperglycemic Emergency treatment of
hyperkalaemia
8- Adverse effects -
- Hypoglycaemia
- Lipodystrophy
- Allergic manifestation
- Insulin resistance
- Edema
9Oral hypoglycaemic drugs - Classification
- Sulfonylureas 1st generation -
Tolbutamide Chlorpropamide 2nd generation
Glibenclamide Glipizide Gliclazide Glime
piride Meglitinide analogues - Repaglinide Nate
glinide
10 Biguanides - Metformin Phenformin Alfa
glucosidase inhibitors - Acarbose Miglitol Thia
zolidinediones Rosiglitazone Pioglitazone
11Sulfonylureas - MOA - Sulfonylureas acts on
beta cells, stimulating insulin secretion and
thus reducing blood glucose levels. Drugs reuce
the permeability of K by competitively blocking
the sulfonylureas receptors present on ATP
sensitive K channels , causing depolarisation,
Ca2 entry and insulin secretion. Adverse
effects - Hypoglycaemia Weight gain, nausea,
vomiting, diarrhoea, constipation ,
agranulocytosis, hypersensitivity, cholestatic
jaundice.
12PK - Absorbed orally, high plasma protein
bindint(90-98) Metabolized in liver , excreted
in urine Duration of action 6-12 hr It croses
placental barrier it caused hypoglycaemia at
birth CI - Pregnancy Gestational diabetes
13Drug interactions - Drugs that potentiate the
effects of sulfonylureas Oral anticoagulants,
ketoconazole, chloramphenicol (-) metabolism
Salicylates, sulfonamides , clofibrate
displace protein binding sites Drugs that
decrease the effects of sulfonylurease
Phenobarbitone, phenytoin , rifampicin
decrease metabolism corticosteroids, thiadides,
estrogens - Biguanides - ? uptake and
utilization of glucose in skeletal muscle reduce
insulin resistant (-) renal hepatic
gluconeogenesis ? glucose absorption from GIT ?
Plasma glucagon levels
14 Corticosteroids
Classification
- Glucocorticoids Short acting
Hydrocortisone Intermediate acting
Prednisolone Methyl
prednisolone
Triamcinolone Long acting - Betamethasone
Dexamethasone Meneralocorticoids
- Desoxycorticosterone acetate Fludrocortisone
aldosterone
15Mechanism of actions - Corticoids bind to
specific receptor in the cytoplasm , the drug
Receptor complex is transported into the
nucleous where it binds to specific Sites on DNA
and regulates the synthesis of new proteins that
bring about The hormone effects
. Pharmacological actions - Mineralocorticoids
highly effects on Na, k and fluid
balance Glucocorticoids highly effects on
carbohydrate, protein, fat and other. Metabolic
effects - Carbohydrate promote
gluconeogenesis Protein- enhance protein break
down Fat lipolysis, redistribution of fat
16 Antiinflammatory and immunosuppressive effects
- Supress development of inflammatory response
to all types of stimuli inhibit bothLate and
early manifestations of inflammation. Supress
cell mediated immunity, prevent manifestations of
allergy Ca 2 metabolism (-) intestinal
absorption enhance renal excretion of ca2 CVS
- Skeletal muscle - hypocritism,
hypercritism CNS - euphoria Stomach - increase
gastric secretion Lymphoid tissue and blood cells
- increase destruction of lymphoid cells,
increase no. of RBC, neutrophils, platelets.
17- Therapeutic uses -
- Replacement therapy
- Acute adrenal insufficiency
- Chronic adrenal insufficiency
- Congenital adrenal hyperplasia
- Pharmacotherapy
- Arthritides NSAIDS glucocorticoids
- Rheumatoid arthritis
- Osteoarthritis
- Rheumatic fever
- Gout
- Collagen diseases SLE, nephrotic syndrome,
glomerulonethritis - Severe allergic reactions angioneuotic edema,
urticaria and serum sickness
18- Autoimmune diseases haemolytic anaemia,
thrombocytopenia, - chronic hepatitis
- Bronchial asthma status asthmaticus, acute
asthma excerbation - Other lung diseases Pulmonary edema
aspiration penumonia - Infective diseases tuberculosis, severe
lepra reaction - Eye diseases keratitis, iridocyclitis,
iritis, allergic conjuctivitis, prevent
blindness - Skin diseases exfoliative dermatitis,
stevens hohnson syndrome - Intestinal diseases ulcerative colitis,
coeliac disease - Cerebral edema
- Malignancies acute lymphatic leukemia,
hodgkins breast carcinoma - Organ transplantation and skin allograft
liver, kidney, heart transplantation. - Shock
19- Adverse effects -
- Mineralocorticoids hypokalemic alkalosis,
edema, raise in BP - Glucocorticoids -
- Cushings habitus
- Hyperglycaemia
- Muscular weakness
- Delayed healing
- Peptic ulceration
- Osteoporosis
- Galucoma
- Growth retardation
- Foetal abnormalities
20- Psychiatric disturbances
- Suppression of hypothalamo pituitary adrenal
axis - Fragile skin , purple striae
- Contraindications -
- Peptic ulcer
- DM
- HT
- Viral and fungal infections
- Tuberculosis other infections
- Osteoporosis
- Psychosis
- Epilepsy
- CHF
- Renal failure
21THANK U